Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GT-002 Single Ascending Doses in Healthy Men
NCT03817346Phase 1Completed
- Sponsor
- Gabather AB
- Start
- Dec 2018
- Primary completion
- Mar 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in schizophrenia comparing Experimental GT-002 with Placebo Comparator (2 arms). Primary endpoint: Adverse Events (AEs). Started Dec 2018; status: completed.
02
Drugs
GT-002
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03817346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03817346.